Economic evaluation of tandem mass spectrometry newborn screening in Australia

Pediatrics

Volumn 123, Issue 2, 2009, Pages 451-457

  Norman, Richard ^a   Haas, Marion ^a   Chaplin, Meredyth ^a   Joy, Pamela ^b   Wilcken, Bridget ^b,c  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c University of Sydney   (Australia)

Author keywords

Australia; Cost Effectiveness; Metabolism; Newborn; Screening

Indexed keywords

ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INBORN ERROR OF METABOLISM; INFANT MORTALITY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; NEWBORN SCREENING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; COST BENEFIT ANALYSIS; ECONOMICS; NEWBORN;

AUSTRALIA; COST-BENEFIT ANALYSIS; HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 61549130602     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0911     Document Type: Article

References (25)

1. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348(23):2304-2312
2. Roscher AA, Olgemöller B. Newborn screening for inborn errors of metabolism with tandem mass spectrometry in Bavaria, Germany [in German]. LaboratoriumsMedizin. 2004;28(6): 521-524
3. van der Hilst CS, Derks TG, Reijngoud DJ, Smit GP, TenVergert EM. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of the Netherlands. J Pediatr. 2007;151(2):115-120
4. Pandor A, Eastham J, Chilcott J, Paisley S, Beverley C. Economics of tandem mass spectrometry screening of neonatal inherited disorders. Int J Technol Assess Health Care. 2006;22(3): 321-326
5. Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics. 2006;117(5): S287-S295
6. Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health. 2007;10(2):83-97
7. Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem. 2007;40(3-4):235-241
8. Autti-Rämö I, Makela M, Sintonen H, et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatr. 2005;94(8):1126-1136
9. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. 2003;112(5):1005-1015
10. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. 2002; 141(4):524-531
11. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess. 1997;1(7):i-iv, 1-202
12. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics. 2002;110(4):781-786
13. Haas M, Chaplin M, Joy P, Wiley V, Black C, Wilcken B. Healthcare use and costs of medium-chain acyl-CoA dehydro- genase deficiency in Australia: screening versus no screening. J Pediatr. 2007;151(2):121-126
14. New South Wales Department of Health. NSW costs of care standard 2001/2. Available at: www.nsw.gov.au/pubs/a-z/c.asp. Accessed October 1, 2007
15. Wilcken B. More on medium-chain acyl-coenzyme A dehy- drogenase deficiency in a neonate. N Engl J Med. 2008;358(6):647
16. Australian Bureau of Statistics. Year Book Australia 2006. Canberra, Australia: Australian Bureau of Statistics; 2006
17. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276(14):1172-1177
18. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ. 1996;5(2):141-154
19. Stevens K. Working With Children to Develop Dimensions for a Preference Based Generic Paediatric Health Related Quality of Life Measure. Sheffield, England: University of Sheffield; 2008
20. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeco-nomics. 2001;19(11):1103-1109
21. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007;16(3):307-317
22. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet. 2007;369(9555): 37-42
23. Hanley WB. Adult phenylketonuria. Am J Med. 2004;117(8):590-595
24. Joy P, Black C, Rocca A, Haas M, Wilcken B. Neuropsychological functioning in children with medium chain acyl coenzyme A dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome. Child Neuropsychol. 2008; Apr 3:1-13
25. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47(11):1945-1955